Trifluoperaizne (TFP) is an antipsychotic medication with limited oral bioavailability due to extensive first-pass metabolism; consequently, the goal of this project was to develop Leciplex nanoparticles for intranasal administration to circumvent oral issues. Leciplex NPs were formulated and optimized using the 21 31 full factorial statistical design. The formulae were characterized regarding their particle size (PS), polydispersity index (PDI), zeta potential (ZP), entrapment efficiency percentages (EE %), and the amount of drug released after 6 hours (Q6h).
Optimized formula was selected based on the multilevel categoric model and contained DDAB as SAA and had a PL-90G:SAA ratio of 1:1. It was showed a PS of 174.79 nm, a PDI of 0.241, a ZP of 38.21 mV, an EE% of 53.59 % and a Q6h of 65.58 %. Thus, it can be inferred that the developed Leciplex could effectively be explored as a promising nasal delivery of TFP in the effective treatment of depression.